Published in Cancer Weekly, November 29th, 2011
According to Lodge, the Company's lead product BREVAGen™, a predictive risk assessment tool for assessing women's risk of developing breast cancer, is demonstrating early success within its sales cycle in the US.
Importantly, the key drivers underpinning the future success of BREVAGen as a standard tool in assessing women's risk of developing breast...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.